Physician profile
Vincent E Rampersaud
NPI 1144348152
$24,224.35
in general payments reported to CMS, 2019-2025
31 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $546 · 2021: $349 · 2022: $1,479 · 2023: $1,479 · 2024: $6,422 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,185 · Consulting Fee: $8,100 · Travel and Lodging: $4,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,185.19 |
| Consulting Fee | $8,100.00 |
| Travel and Lodging | $4,032.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $11,385.43 | 2021-2025 | Nalu Neurostimulation System |
| Nevro Corp. | $1,851.90 | 2020-2024 | Senza |
| Boston Scientific Corporation | $1,804.37 | 2019-2025 | General - Pain Management, Intracept Rf Probe, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $1,676.07 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $1,525.43 | 2025 | Evoke |
| Abbvie INC. | $1,200.47 | 2022-2025 | |
| Globus Medical, INC. | $928.70 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Horizon Therapeutics Plc | $779.75 | 2019-2022 | |
| Forte Bio-Pharma LLC | $665.20 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Abbott Laboratories | $504.57 | 2019-2024 | Proclaim |
| Stryker Corporation | $303.05 | 2023-2025 | Spinejack, Mild Device Kit |
| Brixton Biosciences, INC. | $302.65 | 2024-2025 | Neural Ice |
| Averitas Pharma INC. | $208.31 | 2023-2024 | Qutenza |
| Painteq LLC | $185.63 | 2023-2024 | Painteq |
| Curonix LLC | $155.49 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $149.51 | 2025 | Ha Minuteman G3-R |
| Mml US, INC. | $134.80 | 2022 | |
| Si-Bone, INC. | $117.35 | 2020-2025 | |
| Medtronic USA, INC. | $67.53 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.25 | 2022 | |
| Pfizer INC. | $37.33 | 2019-2020 | |
| Allergan, INC. | $31.23 | 2019 | |
| Biodelivery Sciences International, INC. | $31.04 | 2019-2021 | |
| Tersera Therapeutics LLC | $30.16 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.97 | 2024 | |
| Relievant Medsystems, INC. | $21.86 | 2020 | |
| Merz North America, INC. | $18.60 | 2022 | |
| Bioventus LLC | $16.19 | 2019 | |
| Hydrocision, INC. | $11.88 | 2019 | |
| Grt US Holding, INC. | $10.63 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Rampersaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.